TABLE V: Therapeutic/pharmacological trials in mouse OA models where no comparative data in GM mice is available.

Therapeutic target

Treatment

OA feature targeted by the treatment

Effect on OA joint pathology‡

Effect on OA symptoms

OA phenotype evaluated**&

Validated#
             

‡Cartilage erosion, subchondral bone thickening, osteophytes, and synovitis.

**OA phenotype: post-traumatic (ptOA: ACLT = anterior cruciate ligament transection; ACLR = non-surgical mechanically induced anterior cruciate ligament rupture; DMM = surgical destabilization of the medial meniscus; iaF = intra-articular fracture; MULTI = transection of anterior and posterior cruciate ligaments, medial and lateral collateral ligaments and medial and lateral meniscectomy; s/rJL = single or repetitive joint loading without causing ligament failure; TMCL/MM = transection of the medial collateral ligament and partial or complete medial meniscectomy), over-use (ouOA: e.g. excessive or high-speed running, forced use of one limb by inhibiting load-bearing on another), spontaneous age-associated (aaOA), ovariectomy (ovxOA, high bone turnover), collagenase-induced (ciOA; more inflammatory), post-inflammatory (piOA; e.g. with sufficient time post AIA induction inflammation subsides and pathology is typical of OA), monoidoacetate-induced (miOA; chondrocyte death and marked subchondral bone erosion), papain-induced (papOA; proteolysis of cartilage aggrecan).

&It is recognized that there is continuing debate about whether some of the included models should be considered “OA”, and their inclusion here should not be considered an endorsement. However, until such time as it becomes clear which models do or do not provide information that translates to similar outcomes in human OA, these have been included.

#Validation indicates similar therapeutic studies have been done another animal model of OA. ‘Yes’ means the validation study reported the expected or same result versus the original study; ‘No’ means the validation study reported a different effect.

 

References

  1. Chen, L. et al. IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis. Osteoarthritis Cartilage 19, 711-8 (2011).
  2. Burleigh, A. et al. Joint immobilization prevents murine osteoarthritis and reveals the highly mechanosensitive nature of protease expression in vivo. Arthritis Rheum 64, 2278-88 (2012).
  3. Diekman, B.O. et al. Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents post-traumatic arthritis. Cell Transplant (2012).
  4. Carames, B. et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis 71, 575-81 (2012).
  5. Song, J. et al. MicroRNA-181b regulates articular chondrocytes differentiation and cartilage integrity. Biochem Biophys Res Commun (2013).
  6. McNamee, K.E. et al. Treatmentof murine osteoarthritis withTrkAd5 reveals a pivotal rolefor nerve growth factor in non-inflammatory joint pain. Pain 149, 386-92 (2010).
  7. Kadri, A. et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann Rheum Dis 69, 1533-8 (2010).